HomeCompareCMPI vs ORCC

CMPI vs ORCC: Dividend Comparison 2026

CMPI yields 19.05% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMPI wins by $47.5K in total portfolio value
10 years
CMPI
CMPI
● Live price
19.05%
Share price
$10.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.9K
Annual income
$6,079.53
Full CMPI calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CMPI vs ORCC

📍 CMPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMPIORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMPI + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMPI pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMPI
Annual income on $10K today (after 15% tax)
$1,619.05/yr
After 10yr DRIP, annual income (after tax)
$5,167.60/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CMPI beats the other by $5,166.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMPI + ORCC for your $10,000?

CMPI: 50%ORCC: 50%
100% ORCC50/50100% CMPI
Portfolio after 10yr
$45.1K
Annual income
$3,040.29/yr
Blended yield
6.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CMPI
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMPI buys
0
ORCC buys
0
No recent congressional trades found for CMPI or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMPIORCC
Forward yield19.05%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$68.9K$21.4K
Annual income after 10y$6,079.53$1.04
Total dividends collected$38.2K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: CMPI vs ORCC ($10,000, DRIP)

YearCMPI PortfolioCMPI Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$12,605$1,904.76$11,190$489.61+$1.4KCMPI
2$15,731$2,243.84$12,229$256.01+$3.5KCMPI
3$19,449$2,617.14$13,216$130.74+$6.2KCMPI
4$23,835$3,024.07$14,207$66.02+$9.6KCMPI
5$28,967$3,463.51$15,234$33.17+$13.7KCMPI
6$34,928$3,933.88$16,317$16.62+$18.6KCMPI
7$41,806$4,433.18$17,468$8.32+$24.3KCMPI
8$49,692$4,959.03$18,695$4.16+$31.0KCMPI
9$58,679$5,508.79$20,006$2.08+$38.7KCMPI
10$68,866$6,079.53$21,407$1.04+$47.5KCMPI

CMPI vs ORCC: Complete Analysis 2026

CMPIStock

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Full CMPI Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CMPI vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMPI vs SCHDCMPI vs JEPICMPI vs OCMPI vs KOCMPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.